A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
Open Access
- 1 September 2019
- journal article
- review article
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 12, 1897-1911
Abstract
Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of <70 mg/dL or target non-high-density lipoprotein goal of <100 mg/dL. Lipid-lowering therapies (LLTs), such as statins and ezetimibe, are the cornerstone for plasma LDL-C lowering; however, individuals with diabetes are often unable to achieve target lipid goals with these therapies alone and frequently require additional treatments. A new class of LLTs, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, provides a novel approach to lowering lipids in persons with high CV risk, such as those with diabetes. The clinical data presented in this review indicate the potential benefits of alirocumab in patients with diabetes and its value as a treatment option in patients with diabetic dyslipidemia with no significant safety concerns.Keywords
This publication has 36 references indexed in Scilit:
- Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)The American Journal of Cardiology, 2014
- Lipid lowering with PCSK9 inhibitorsNature Reviews Cardiology, 2014
- Atorvastatin with or without an Antibody to PCSK9 in Primary HypercholesterolemiaNew England Journal of Medicine, 2012
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialThe Lancet, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJACC, 2012
- Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolNew England Journal of Medicine, 2012
- Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levelsProceedings of the National Academy of Sciences, 2009
- Dyslipidemia in type 2 diabetes mellitusNature Reviews Endocrinology, 2009
- Diabetes and Cardiovascular DiseaseCirculation, 1999
- The Low-Density Lipoprotein Pathway and its Relation to AtherosclerosisAnnual Review of Biochemistry, 1977